We aim to provide evidence-based guidance on best clinical practice in the provision, monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition. The guidelines include:
(i) Guidance on risk assessment prior to PrEP;
(ii) Baseline assessment;
(iii) Dosing schedules;
(v) Supporting adherence;
(vi) Buying generic PrEP; and
The guidelines are aimed at clinical professionals directly involved in, and responsible for, HIV prevention, and at community advocates and organisations responsible for supporting HIV prevention strategies in those at risk of HIV acquisition.
A detailed review of the evidence base is included in Section 4. Sections 5 to 7 are intended to offer practical guidance in risk assessment, starting PrEP, ongoing management while on PrEP and stopping PrEP.
The comments with replies from the Writing group can be downloaded here:
Non-technical information on PrEP
Please see below for links to other organisations with non-technical information about PrEP:
(NB These are links to external sites for which BHIVA has no responsibility)
|Michael Brady||Consultant in Sexual Health and HIV, King’s College Hospital, London|
|Alison Rodger||Reader and Honorary Consultant Infectious Diseases and HIV, University College London|
|David Asboe||Consultant HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London|
|Valentina Cambiano||Lecturer in Infectious Disease Modelling and Biostatistics, University College London|
|Dan Clutterbuck||Consultant HIV and Sexual Health, NHS Lothian|
|Monica Desai||Consultant Epidemiologist, Public Health England|
|Nigel Field||Senior Lecturer, Consultant Clinical Epidemiologist, University College London|
|Justin Harbottle||Programme Officer, Terrence Higgins Trust, London|
|Zahra Jamal||Policy and Research Officer, NAZ, London|
|Sheena McCormack||Professor of Clinical Epidemiology, MRC Clinical Trials Unit at University College London|
|Adrian Palfreeman||Consultant HIV and Sexual Health, University Hospitals of Leicester NHS Trust|
|Mags Portman||Consultant HIV and Sexual Health, Mortimer Market Centre, London|
|Killian Quinn||Consultant HIV and Sexual Health, King’s College Hospital, London|
|Melinda Tenant-Flowers||Retired Consultant in HIV and Sexual Health Medicine, King’s College Hospital, London|
|Ed Wilkins||Consultant in Infectious Diseases, North Manchester General Hospital|
|Ingrid Young||Chancellor's Fellow, Usher Institute, University of Edinburgh|
A full list of conflict of interest statements is available on request from BHIVA.
The guidelines will be fully updated and revised in 2023. However, in the interim, new information from high-quality studies will be considered and where this is thought to be clinically important to ensure continued best clinical practice, the guidelines will be revised.